Abstract: An apparatus for treating an aneurysm in a blood vessel includes an occlusion element configured to be releasably coupled to an elongate delivery shaft and configured to be delivered in a collapsed configuration through an inner lumen of a delivery catheter, the occlusion element including an inverted mesh tube having an outer layer and an inner layer, the outer layer transitioning to the inner layer at an inversion fold, wherein at least the outer layer is formed into a first expanded shape including: a smooth outer cylinder configured to engage a wall of an aneurysm throughout a 360° circumference; and a substantially distal-facing surface including one or more heat-formed undulations, the one or more undulations configured to apply a radial force on the wall of the aneurysm.

Abstract: Systems and methods permit or cause content to be displayed by a plurality of gaming displays, such as gaming machine displays and/or external displays. Content may be synchronously displayed by multiple gaming displays, such as one or more EGM displays and one or more external gaming displays, where the content which is displayed by the different displays may be the same or be different, and may be provided by a content controller and/or may be provided or triggered by a gaming machine. The systems and methods permit or cause content to be synchronously displayed across multiple gaming displays, such as in time and/or space. In some examples, the content is configured as a content “package” which is associated with one or more displays.

Abstract: Systems and methods for data anomaly detection include recommending one or more algorithms from a set of algorithms to process received time series data, wherein the one or more algorithms are recommended based at least in part on a type of workload for processing the received time series data. Assisted parameter tuning is provided for a detected anomaly alert and calibration, and the received time series data is processed based on a user selected algorithm that is parameter tuned, thereby resulting in more efficient and reliable anomaly detection.

Abstract: A protective circuit can include an AC line configured to provide power from an AC source, and a first protection circuit coupled to the AC line and implemented to be electrically parallel with a load circuit. The first protection circuit can be configured to be in an inactive state to be substantially non-conducting when a voltage across the load circuit is in a normal range or an active state to be substantially conducting when the voltage across the load circuit has an overvoltage value greater than the normal range to shunt power away from the load circuit. The protective circuit can further include a second protection circuit implemented to be electrically between the AC source and the load circuit. The second protection circuit can be configured to block power from the AC source in response to a condition resulting from the first protection circuit being in the active state.

Abstract: A heat-not-burn (HNB) aerosol-generating device may include a capsule and a device body. The capsule may include an aerosol-forming substrate and a conductive component. The conductive component may include a first end section, an intermediate section, and a second end section. The intermediate section may be configured to heat the aerosol-forming substrate. The first end section and the second end section may each have at least one surface discontinuity. The device body may include connector pins configured to engage with the at least one surface discontinuity of each of the first end section and the second end section of the conductive component so as to establish an electrical connection with the capsule.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

Abstract: In some examples, a multilevel retort assembly. The assembly includes a base defining a base perimeter; and a plurality of shells. Each shell has a diffuser plate support and a perimeter with a substantially similar shape as the base perimeter. The plurality of shells are stacked on each other, mechanically supported by the base, and surround an inner retort volume. The at least one shell of the plurality of shells defines a removable window. The assembly also includes a plurality of diffuser plates, each diffuser plate supported by a corresponding diffuser plate support of the plurality of diffuser plate supports.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: A rotor assembly for a peristaltic pump is provided. Each of a first pair of roller assemblies includes a first roller portion having a first diameter and a second roller portion having a second diameter. The first diameter is larger than the second diameter. Each of a second pair of roller assemblies includes a first roller portion having a first diameter and a second roller portion having a second diameter. The first diameter is smaller than the second diameter. The first and second pairs of roller assemblies are positionable around a circumference of a hub such that the first roller portion of the first pair of roller assemblies is aligned with the first roller portion of the second pair of roller assemblies and the second roller portion of the first pair of roller assemblies is aligned with the second roller portion of the second pair of roller assemblies.

Abstract: A power control system for an aerosol-generating device includes at least one processor and a memory. The memory is coupled to the at least one processor and is configured to store instructions. The at least one processor is configured to execute the instructions to cause the power control system to determine whether a first power to be applied to a heater of the aerosol-generating device exceeds a power threshold, in response to the first power exceeding the power threshold, apply a second power to the heater, and in response to the first power not exceeding the power threshold, apply the first power to the heater. The first power is based on a desired heater temperature. The second power does not exceed the power threshold.

Abstract: A session control system for a device includes at least one processor and a memory coupled to the at least one processor. The memory is configured to store instructions. The at least one processor is configured to execute the instructions to cause the session control system to detect when a session has started, start a session timer, increment a puff variable when an airflow sensor detects that a puff has been taken, monitor the session timer against a time threshold and the puff variable against a puff threshold, and in response to a session threshold being met, end the session. The session timer is configured to measure a length of the session and the puff variable corresponds to a total number of puffs taken.

Abstract: A cooldown system for a device includes at least one processor and a memory coupled to the at least one processor. The memory is configured to store instructions. The at least one processor is configured to execute the instructions to cause the cooldown system to detect when a session has ended, activate a cooldown timer to measure a cooldown time, provide an indication of a remaining time of the cooldown timer, and in response to the cooldown timer elapsing, return the device to normal operation.

Abstract: A charging system for an aerosol-generating device includes a processor and a memory in communication with the processor and configured to store instructions is provided. The instructions define at least one of a disable mode, an intra-session mode, or an inter-session mode. The processor is configured to execute the instructions to cause the charging system to detect when the device is connected to a charging device; activate a power source charger in response to the connection to the charging device; identify a selected mode; enable or disable a heater of the capsule dependent upon the selected mode; if the heater is enabled, display a first display indicating the connection of the charging device; if the heater is enabled, detect if a session of the aerosol-generating device is ongoing; and if the session is ongoing, enable or suspend charging in response to the identification of the selected mode.

Abstract: A heat-not-burn aerosol-generating device includes a housing that defines a capsule-receiving cavity and a lid fixedly coupled to the housing at a first point and releasably coupleable to the housing at a second point that is different from the first point. The lid is configured to cover the capsule-receiving cavity in a closed position. The lid includes a first retainer and a replaceable mouthpiece coupleable to the lid such that air entering the housing and drawn through the capsule-receiving cavity exits out of the replaceable mouthpiece. The mouthpiece includes a second retainer that is configured to engage with the first retainer so as to releasably secure the replaceable mouthpiece to the lid.

Abstract: A capsule monitoring system for an aerosol-generating device includes at least one processor and a memory. The memory is coupled to the at least one processor and storing instructions. The at least one processor is configured to execute the instructions to cause the capsule monitoring system to detect a mechanism detection switch of the aerosol-generating device being actuated, apply a first power to a first contact point of the aerosol-generating device, determine a first resistance between the first contact point and a second contact point, determine whether the first resistance is within a resistance operation range, and in response to the first resistance being within of the resistance operation range, display a capsule accepted indicator. The first contact point is configured to contact a heater. The second contact point is configured to contact the heater.

Abstract: Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.

Abstract: Systems and methods for data anomaly detection include recommending one or more algorithms from a set of algorithms to process received time series data, wherein the one or more algorithms are recommended based at least in part on a type of workload for processing the received time series data. Assisted parameter tuning is provided for a detected anomaly alert and calibration, and the received time series data is processed based on a user selected algorithm that is parameter tuned.

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.